



August 24, 2020

Veracyte Named a San Francisco Bay Area “Top Workplace” for Seventh Consecutive Year

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 24, 2020-- [Veracyte, Inc.](#) (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has been awarded a Top Workplaces 2020 honor by the Bay Area News Group for the seventh consecutive year. The annual award is based solely on employee feedback gathered through an anonymous, third-party survey.

“I am so proud that as our company continues to grow and evolve, including expanding internationally, we’ve been able to maintain our positive and inclusive work culture,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “We strive to ensure our more than 325 employees feel appreciated, well informed and empowered to share their points of view, and it is so gratifying to see our efforts reflected in the 2020 Top Workplace survey responses.”

The Top Workplaces award winners are determined by results of a survey administered by Energage, LLC, a leading provider of technology-based engagement tools. The survey measures several key aspects of workplace culture, including organizational alignment, effective execution and meaningful connection with employees.

Veracyte’s innovation and industry leadership have been recognized consistently since the company was founded in 2008. Employees participating in the 2020 Top Workplaces survey ranked the company most highly for “doing things efficiently and well,” having senior managers who understand what is happening at the company, having strong interdepartmental coordination, encouraging different points of view, and making employees feel well-informed about important decisions at the company.

“These responses reflect our deep commitment to improving the lives of patients, which requires that we trust and collaborate with each other and that we constantly seek opportunities to improve how we work together,” said Ms. Anderson.

The Bay Area News Group published the complete list of 2020 Top Workplaces on Sunday, August 23. The list of winners is available at the Bay Area News Group website.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of tests leverage deep genomic insights, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements NEEDS UPDATING

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding Veracyte’s expectations for growth and expansion and the retention of work culture as Veracyte expands. Forward-looking statements are neither historical facts nor assurances of future performance, but are based only on our current beliefs, expectations and assumptions. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: the impact of COVID-19 on Veracyte’s business and operating results, specifically, and the healthcare system and economy more generally, Veracyte’s ability to achieve and maintain Medicare coverage for its tests; the benefits of Veracyte’s tests and the applicability of clinical results to actual outcomes; the laws and regulations applicable to Veracyte’s business, including potential regulation by the Food and Drug Administration or other regulatory bodies; Veracyte’s ability to successfully achieve and maintain adoption of and reimbursement for its products; the amount by which use of Veracyte’s products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; and other risks set forth in Veracyte’s filings with the Securities and Exchange Commission, including the risks set forth in its quarterly report on Form 10-Q for the quarter ended June 30, 2020. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, Afirma, Percepta, Envisia, Prosigna, LymphMark, and the Veracyte logo are trademarks of Veracyte, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200824005106/en/): <https://www.businesswire.com/news/home/20200824005106/en/>

Investor and Media Contact:

Tracy Morris
Vice President of Corporate Communications
& Investor Relations
650-380-4413
tracy.morris@veracyte.com

Source: Veracyte, Inc.